Majid Afshar1, Clayton L Foster2, Jennifer E Layden3, Ellen L Burnham4. 1. Department of Medicine, Loyola University Chicago Health Sciences Campus, Maywood, IL; Department of Public Health Sciences, Stritch School of Medicine, Loyola University Chicago Health Science Campus, Maywood, IL. Electronic address: majid.afshar@luhs.org. 2. Division of Infectious Diseases, Department of Medicine, University of Colorado School of Medicine, Aurora, CO. Electronic address: clayton.foster@ucdenver.edu. 3. Department of Medicine, Loyola University Chicago Health Sciences Campus, Maywood, IL; Department of Public Health Sciences, Stritch School of Medicine, Loyola University Chicago Health Science Campus, Maywood, IL. Electronic address: jlayden@lumc.edu. 4. Division of Pulmonary Sciences and Critical Care Medicine, Department of Medicine, University of Colorado School of Medicine, Aurora, CO. Electronic address: ellen.burnham@ucdenver.edu.
Abstract
PURPOSE: Studies investigating the association between macrolides and outcomes in both pulmonary and nonpulmonary critically ill patients are limited. We aimed to examine the association between azithromycin use and clinical outcomes in severe sepsis patients with and without pneumonia receiving mechanical ventilation. MATERIALS AND METHODS: A retrospective cohort of 105 patients admitted to an adult intensive care unit (ICU) with severe sepsis in an urban university hospital were included in the study. Multivariable linear regression was performed to assess the relationship between azithromycin use and the following outcomes: 28-day ICU-free days and 28-day ventilator-free days. RESULTS: In univariate analysis, patients receiving azithromycin had nearly 6 more ICU-free days on average than did patients not receiving azithromycin (P = .005). The increased ICU-free days remained in multivariable analysis adjusting for age, sex, race, ICU type, and presence of shock (P = .005). In stratified analysis examining the association of azithromycin use in severe sepsis patients without pneumonia (n = 74), the results were similar to the full cohort. CONCLUSION: Azithromycin was associated with more ICU-free days in severe sepsis patients with and without pneumonia. Further investigations are warranted to better elicit the association of macrolide use on clinical outcomes in severe sepsis patients, especially those without pneumonia.
PURPOSE: Studies investigating the association between macrolides and outcomes in both pulmonary and nonpulmonary critically illpatients are limited. We aimed to examine the association between azithromycin use and clinical outcomes in severe sepsispatients with and without pneumonia receiving mechanical ventilation. MATERIALS AND METHODS: A retrospective cohort of 105 patients admitted to an adult intensive care unit (ICU) with severe sepsis in an urban university hospital were included in the study. Multivariable linear regression was performed to assess the relationship between azithromycin use and the following outcomes: 28-day ICU-free days and 28-day ventilator-free days. RESULTS: In univariate analysis, patients receiving azithromycin had nearly 6 more ICU-free days on average than did patients not receiving azithromycin (P = .005). The increased ICU-free days remained in multivariable analysis adjusting for age, sex, race, ICU type, and presence of shock (P = .005). In stratified analysis examining the association of azithromycin use in severe sepsispatients without pneumonia (n = 74), the results were similar to the full cohort. CONCLUSION:Azithromycin was associated with more ICU-free days in severe sepsispatients with and without pneumonia. Further investigations are warranted to better elicit the association of macrolide use on clinical outcomes in severe sepsispatients, especially those without pneumonia.
Authors: Lionel A Mandell; Richard G Wunderink; Antonio Anzueto; John G Bartlett; G Douglas Campbell; Nathan C Dean; Scott F Dowell; Thomas M File; Daniel M Musher; Michael S Niederman; Antonio Torres; Cynthia G Whitney Journal: Clin Infect Dis Date: 2007-03-01 Impact factor: 9.079
Authors: Guy G Brusselle; Christine Vanderstichele; Paul Jordens; René Deman; Hans Slabbynck; Veerle Ringoet; Geert Verleden; Ingel K Demedts; Katia Verhamme; Anja Delporte; Bénédicte Demeyere; Geert Claeys; Jerina Boelens; Elizaveta Padalko; Johny Verschakelen; Georges Van Maele; Ellen Deschepper; Guy F P Joos Journal: Thorax Date: 2013-01-03 Impact factor: 9.139
Authors: I Martin-Loeches; T Lisboa; A Rodriguez; C Putensen; D Annane; J Garnacho-Montero; M I Restrepo; J Rello Journal: Intensive Care Med Date: 2009-12-02 Impact factor: 17.440
Authors: Carolyn M Hendrickson; Jason Abbott; Hanjing Zhuo; Kathleen D Liu; Carolyn S Calfee; Michael A Matthay Journal: Am J Physiol Lung Cell Mol Physiol Date: 2017-02-17 Impact factor: 5.464
Authors: Tom D Y Reijnders; Hessel Peters-Sengers; Lonneke A van Vught; Fabrice Uhel; Marc J M Bonten; Olaf L Cremer; Marcus J Schultz; Martijn M Stuiver; Tom van der Poll Journal: Crit Care Date: 2022-05-24 Impact factor: 19.334
Authors: Simone S Schüller; Boris W Kramer; Eduardo Villamor; Andreas Spittler; Angelika Berger; Ofer Levy Journal: Front Pediatr Date: 2018-07-19 Impact factor: 3.418
Authors: Gerwyn Morris; Eugene Athan; Ken Walder; Chiara C Bortolasci; Adrienne O'Neil; Wolf Marx; Michael Berk; André F Carvalho; Michael Maes; Basant K Puri Journal: Life Sci Date: 2020-10-06 Impact factor: 6.780
Authors: Gaber El-Saber Batiha; Marwa A Zayed; Aya A Awad; Hazem M Shaheen; Suleiman Mustapha; Oscar Herrera-Calderon; Jorge Pamplona Pagnossa; Abdelazeem M Algammal; Muhammad Zahoor; Achyut Adhikari; Ishan Pandey; Sara T Elazab; Kannan R R Rengasamy; Natália Cruz-Martins; Helal F Hetta Journal: Front Med (Lausanne) Date: 2021-04-14